Novel TBL1 targeting strategy drives nuclear β-catenin degradation, inhibits oncogenic transcription, and demonstrates potent anti-tumor activity in complex solid tumors The company continues to build clinical momentum in hepatocellular carcinoma while expanding development into colorectal cancer, as well as other Wnt-driven cancers April 13, 2026 -- Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American

Mackay Base Hospital activated March 31, 2026 as first clinical trial site; first patient dosed within days of activation — a signal of strong enrollment velocity and significant unmet medical need April 13, 2026 -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that the first patient has been dosed in its ongoing Phase IIa clinical trial evaluating ONP-002,

The FDA on Monday approved Travere Therapeutics' dual endothelin angiotensin receptor antagonist Filspari (sparsentan) to reduce proteinuria in focal segmental glomerulosclerosis (FSGS), giving patients their first authorised therapy for the rare kidney disorder. The green light also extends the drug's reach beyond its earlier use in IgA nephropathy. The new indication applies to adults and children aged eight years and older with FSGS who do not have nephrotic syndrome. "This approval…builds

April 13, 2026 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that results from both the ovarian cancer cohort and the cervical cancer cohort of Phase II study SKB264-II-06/MK-2870-002 of the TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination with MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]), were selected for oral presentation at the 2026 Society of Gynecologic Oncolo

April 13, 2026- Health Canada has granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab injection) for subcutaneous self-administration via a single-use autoinjector for adult patients with active, autoantibody positive systemic lupus erythematosus (SLE) in addition to standard therapy. The approval by Health Canada was based on positive results from the interim analysis of the Phase III TULIP-SC trial. In the trial, the subcutaneous administration of anifrolumab led to a statistically

BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control arm This trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to current practice These results mark the fourth positive Phase 3 study of pirtobrutinib in CLL April 13, 2026 -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-coval

Clinical results from Caliway's CBL-0204 Phase 2b study of its fat reduction drug candidate CBL-514 for localized fat reduction have been accepted by the Aesthetic Surgery Journal (ASJ), a leading academic journal in aesthetic medicine and plastic surgery. Following the publication of CBL-16001 Phase 2a results in 2022 and CBL-0202 Phase 2 results in 2025, this marks another ASJ acceptance for CBL-514, reflecting continued recognition and attention from top international professional communities

UCB will present additional studies and data analyses highlighting UCB's ongoing commitment to improving outcomes for people living with gMG Two studies assessed the bioequivalence and effectiveness of zilucoplan auto-injector (ZLP-AI) administration compared with pre-filled syringe (ZLP-PFS)1 UCB is presenting 21 abstracts in total from its innovative neurology portfolio including 14 epilepsy abstracts and six myasthenia gravis (MG) abstracts at AAN 2026 April 13, 2026 -- UCB, a global biophar

Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU for children two to 11 years of age is based on data from the LIBERTY-CUPID clinical study program, including an extrapolation of efficacy data showing that Dupixent significantly reduced urticaria activity compared with placebo in adults The latest approval expands Dupixent’s indication for CSU in the EU to children as young as two years;

April 10, 2026 - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application (ANDA) for Semaglutide Injection, marking a significant milestone in expanding affordable access to complex peptide therapies for patients across the United States. This approval reinforces Apotex's leadership in bringing high value, technically challenging medicines that help improve patient access and support a more sustain